October 21, 2019
BlackThorn Therapeutics names new Chief Executive Officer
BlackThorn Therapeutics has named William J. Martin, Ph.D., as Chief Executive Officer to Lead Next Stage of Growth.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 21, 2019
Stelara data show long-term results in patients with active ulcerative colitis in phase 3 extension trial
BARCELONA, Spain–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of…
October 21, 2019
Charles River Laboratories announces offering of $500 Million of senior notes
WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $500 million in aggregate…
October 21, 2019
Rheos Medicines welcomes Barbara S. Fox as Chief Executive Officer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients…
October 21, 2019
Genentech’s Tecentriq combo with Avastin increases overall survival in people with Unresectable Hepatocellular Carcinoma
Genentech’s Tecentriq’s First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the…
October 21, 2019
Verseau launches with $50M to develop first-in-class macrophage-targeted immunotherapies and appoints George Golumbeski as Chairman of the Board
Verseau has launched with $50M to work on PSGL-1, which has been identified as lead macrophage checkpoint modulator (MCM) program…
October 21, 2019
Circassia Pharmaceuticals launches Duaklir Pressair for Chronic Obstructive Pulmonary Disease (COPD)
Circassia Pharmaceuticals Inc. has launched Duaklir, aclidinium bromide and formoterol fumarate, for the maintenance treatment of patients with chronic obstructive…
October 20, 2019
Vertex reimburses Cystic Fibrosis Medicines Symdeko for patients ages 12 and Older, and Orkambi in children ages 2 to 5, with certain CFTR mutations in Australia
Vertex has reimburseed Cystic Fibrosis Medicines Symdeko for patients ages 12 and Older, and Orkambi in children ages 2 to…
October 18, 2019
CHMP Grants Positive Opinion for Expanded Use of Janssen’s Darzalex for certain multiple myeloma patients
BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human…
October 18, 2019
Vertex gets European CHMP positive opinion for Kalydeco for certain infants with cystic fibrosis as early as 6 months of age
Vertex has received European CHMP positive opinion for Kalydeco (ivacaftor) to treat eligible infants with cystic fibrosis as early as…